Celldex (CLDX) stays a Strong Buy as barzolvolimab hits Phase 3 CSU catalysts and CDX-622 advances; see 2026 data timeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results